XNAS
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.56 | -0.61 | -8.93% | $1.2M | ❌ Miss | -0.60% | -5.93% | — |
| 2026-03-05 | Q4 2025 | -0.58 | -0.60 | -3.45% | $3.9M | ❌ Miss | -1.86% | -2.48% | -16.15% |
| 2025-11-11 |
| Q3 2025 |
| -0.56 |
| -0.55 |
| +1.79% |
| $8.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.64 | -0.54 | +15.62% | $8.5M | ✅ Beat | +1.06% | -2.66% | +0.53% |
| 2025-03-17 | Q4 2024 | -0.58 | -0.63 | -8.62% | $9.6M | ❌ Miss | -7.98% | -12.23% | -21.28% |
| 2024-11-13 | Q3 2024 | -0.78 | -0.45 | +42.31% | $11.5M | ✅ Beat | -10.90% | -21.80% | +53.55% |
| 2024-08-14 | Q2 2024 | -0.65 | -0.29 | +55.38% | $20.0M | ✅ Beat | -5.48% | +7.10% | -12.90% |
| 2024-05-14 | Q1 2024 | -0.80 | -1.19 | -48.75% | $11.2M | ❌ Miss | +3.98% | +8.56% | -8.26% |
Showing last 8 quarters.